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Kaiserslautern, Germany; and **European Molecular Biology Laboratory, Outstation Hamburg, Hamburg, GermanyABSTRACT Bacterial endotoxins (lipopolysaccharides (LPS)) are strong elicitors of the human immune system by interacting
with serum and membrane proteins such as lipopolysaccharide-binding protein (LBP) and CD14 with high specificity. At LPS
concentrations as low as 0.3 ng/ml, such interactions may lead to severe pathophysiological effects, including sepsis and septic
shock. One approach to inhibit an uncontrolled inflammatory reaction is the use of appropriate polycationic and amphiphilic anti-
microbial peptides, here called synthetic anti-LPS peptides (SALPs). We designed various SALP structures and investigated
their ability to inhibit LPS-induced cytokine secretion in vitro, their protective effect in a mouse model of sepsis, and their cyto-
toxicity in physiological human cells. Using a variety of biophysical techniques, we investigated selected SALPs with consider-
able differences in their biological responses to characterize and understand the mechanism of LPS inactivation by SALPs. Our
investigations show that neutralization of LPS by peptides is associated with a fluidization of the LPS acyl chains, a strong
exothermic Coulomb interaction between the two compounds, and a drastic change of the LPS aggregate type from cubic
into multilamellar, with an increase in the aggregate sizes, inhibiting the binding of LBP and other mammalian proteins to the
endotoxin. At the same time, peptide binding to phospholipids of human origin (e.g., phosphatidylcholine) does not cause essen-
tial structural changes, such as changes in membrane fluidity and bilayer structure. The absence of cytotoxicity is explained by
the high specificity of the interaction of the peptides with LPS.INTRODUCTIONBacteria and their pathogenicity factors pose a severe health
problem worldwide because of the increasing occurrence of
resistance as well as the demographic development of pop-
ulations, which is leading to higher numbers of immuno-
compromised people and thus a greater incidence of
severe infections, such as septic shock (1). Despite the avail-
ability of powerful antibiotics, life-threatening bacterial
infections are still a major cause of death due to the inability
of the applied therapeutics to not only kill the bacteria but
also to neutralize their pathogenicity factors, such as endo-
toxins (lipopolysaccharides (LPSs)) and lipoproteins (LPs),
two of the main toxins of Gram-negative and -positive
bacteria, respectively (2). Furthermore, severe septic
diseases are a very frequent complication of primary viral
infections such the Spanish flu and the recent swine flu of
the H1N1 serotype (3). Consequently, most lethal cases
result from the bacterial rather than the viral infection.
Clearly, there is a pressing need for new antimicrobial drugs
that can neutralize bacterial products such as LPS and LP.
A promising strategy is the use of antimicrobial peptides
(AMPs), originally based on LPS-binding domains of defense
proteins suchas lactoferrin (4),NK-lysin (5), andLimulusanti-
LPS factor (6). Treatments based on the use of such peptidesSubmitted January 15, 2011, and accepted for publication April 6, 2011.
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0006-3495/11/06/2652/10 $2.00have been successfully used in animal models of endotoxin-
induced septic shock (7).However, no breakthrough regarding
the development of a therapeutic commercialized drug has
been made, mainly due to the high therapeutic concentrations
of AMPs needed to neutralize endotoxins effectively, which
inevitably causes severe side effects (8).
To circumvent these restrictions, we developed what we
believe is a novel strategy by synthesizing a new class of
peptides, called synthetic anti-LPS peptides (SALPs), which
are designed to strongly bind to the lipid A part of LPS. The
binding constants of these compounds exceed those of
mammalian LPS-bindings proteins such as lipopolysaccha-
ride-binding protein (LBP) and CD14. The design of this
peptide class was based on previously published details
regarding the conformation and physicochemical character-
istics of lipid A and LPS (9). In this way, we constructed
amphiphilic cationic SALPs with lengths optimized for
LPS neutralization, i.e., with a number of amino acid
(AA) residues ranging from 19 to 23 (10). In a mouse model
of lethal sepsis, these peptides were able to neutralize bacte-
rial endotoxins even at very low concentrations and protect
the animals considerably from endotoxic shock. At the same
time, their toxicity levels for mammalian cells were far
higher than the concentrations used in human therapeutics.
To further investigate these favorable properties, we per-
formed a comprehensive biophysical study of peptide
binding to endotoxin to elucidate the mode of action, indoi: 10.1016/j.bpj.2011.04.041
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avoid detrimental side effects in human cells. The results we
obtained using a variety of techniques are indicative of
unique interaction mechanisms, which are discussed further
below in the light of literature data.MATERIALS AND METHODS
Lipids
LPS from the rough mutant Ra from Salmonella minnesota (strain R60) was
extracted by the phenol/chloroform/petrol ether method from bacteria
grown at 37C, purified, and lyophilized (11). The results obtained by stan-
dard assays on the purified LPS (i.e., analyses of the amount of glucos-
amine, total and organic phosphate, and distribution of the fatty acid
residues) were in good agreement with the chemical properties expected
for the LPS chemotypes, whose molecular structure has already been
solved. S-form LPS from Pseudomonas aeruginosa PAO1 for mouse testing
was obtained from the aqueous phase of a water-phenol extract and purified
by treatment with chaotropic agents and detergents according to published
procedures (12). Cholesterol and the phospholipids phosphatidylcholine
(PC) from egg yolk, dioleoylphosphatidylcholine (DOPC), and sphingo-
myelin (SM, 18:1) were obtained from Avanti Polar Lipids (Alabaster, AL).Preparation of LPS or phospholipid aggregates
The LPS and phospholipids were solubilized in the appropriate buffer (lipid
concentrations between 1 nM and 10 mM, depending on the applied tech-
nique), extensively vortexed, sonicated for 30 min in a water bath, and sub-
jected to several temperature cycles between 20C and 60C. Finally, the
lipid suspension was incubated at 4C for at least 12 h before use.Fourier-transform infrared spectroscopy
and differential scanning calorimetry
The measurements of the gel-to-liquid crystalline phase transitions of the
acyl chains of LPS are described in the Supporting Material (13–16).Isothermal titration calorimetry
Microcalorimetric measurements of peptide binding to endotoxins were per-
formed on a MCS isothermal titration calorimeter (Microcal, Freiburg,
Germany)) at 37Caspreviouslydescribed (17).LPSR60 (0.05mM,prepared
as described above) were dispensed into the microcalorimetric cell (volume:
1.3 ml), and the peptide solutions (2 mM) were loaded into the syringe
compartment (volume: 100 ml). After temperature equilibration, the peptides
were titrated in 3 ml portions every 5 min into the lipid-containing cell under
constant stirring, and the heat of interaction after each injection measured by
the isothermal titration calorimetry (ITC) instrument was plotted versus time.
The binding constant of theLPS-peptide interactionwas determined byfitting
the binding curvewith a sigmoidal function and applying common thermody-
namic analysis, i.e., usingDG¼DHTDS (whereDG is theGibbs energy,
T is the temperature, DS is the entropy change, and DH is the measured
enthalpy change). Furthermore, the binding constant kb can be taken from
DG ¼ R  T  ln kb, where R ¼ gas constant. It should be noted that kb
is the reciprocal of the equilibrium dissociation constant kd (kb ¼ 1/kd).X-ray diffraction
X-raydiffractionmeasurementsofLPSR60peptidemixtureswereperformed
at the European Molecular Biology Laboratory outstation at the Hamburgsynchrotron radiation facility (HASYLAB) using the double-focusingmono-
chromator-mirror camera X33 (18). Diffraction patterns in the range of the
scattering vector 0.01 < s < 0.0 nm1 (s ¼ 2 sin q/l, 2q scattering angle,
and wavelength l ¼ 0.15 nm) were recorded at 20C, 40C, and 60C with
exposure times of 1 min using an image plate detector with online readout
(MAR345; MarResearch, Norderstedt/Germany) (19). The s axis was cali-
brated with Ag-Behenate, which has a periodicity of 5.84 nm. We evaluated
the diffraction patterns as described previously (20) by assigning the spacing
ratios of the main scattering maxima to defined three-dimensional structures.
For this study, the lamellar and cubic structures were the most relevant.Freeze-fracture electron microscopy
For freeze-fracturing, LPS and the LPS/peptide samples, copper sandwich
profiles, and instruments formanipulationwere incubatedat roomtemperature
or at 40C.A small amount of the samplewas sandwiched between two copper
profiles as used for the double-replica technique and frozen by plunging the
sandwiches immediately into liquified ethane/propane-mixture cooled in
liquid nitrogen. Fracturing and replication were performed at –150C in
a BAF 400T freeze-fracture device (BAL-TEC, Liechtenstein) equipped
with electron guns and a film sheet thickness monitor. In a first step 2 nm of
Pt(C) were evaporated under an angle of 35, followed by perpendicular evap-
oration of C for a second replica layer of 20 nm thickness. The replicas were
placed on copper grids, cleaned with a chloroform-methanol mixture, and
examined in an EM 901 electron microscope (Zeiss, Oberkochen, Germany).Fluorescence resonance energy transfer
spectroscopy
The ability of the peptides to intercalate into phospholipid liposomes or
LPS R60 aggregates, as investigated by fluorescence resonance energy
transfer (FRET), is described in the Supporting Material.Determination of the z-potential
We used a Zetasizer Nano (Malvern Instruments, Herrsching, Germany) to
determine the z-potentials of endotoxin aggregates from the electrophoretic
mobility by laser-Doppler anemometry at a scattering angle of 90 as
described previously (21). The z-potential was calculated according to
the Helmholtz-Smoluchowski equation from the mobility of the aggregates
in a driving electric field of 19.2 Vcm1. LPS aggregates (0.05 mM) and
peptide stock solutions (1 mM) were prepared in 20 mM Hepes, which
yielded the most reproducible results.Stimulation of human mononuclear cells by LPS
Mononuclear cells (MNCs) were isolated from heparinized blood of healthy
donors as described previously (10). The cells were resuspended in medium
(RPMI 1640) and their number was equilibrated at 5 106 cells/ml. For stim-
ulation, 200 ml MNC (1  106 cells) were transferred into each well of
a 96-well culture plate. LPS Ra and LPS/peptide mixtures were preincubated
for 30 min at 37C, and then added to the cultures at 20 ml per well. The
cultures were incubated for 4 h at 37C under 5% CO2. Supernatants were
collected after centrifugation of the culture plates for 10 min at 400 g and
stored at20C until immunological determination of tumor necrosis factor
a (TNFa), carried out in a Sandwich enzyme-linked immunosorbent assay
using a monoclonal antibody against TNF (clone 6b; Intex AG, Switzerland).Animal model of endotoxicity
LPSs from P. aeruginosa PA01 or S. minnesota R60 (see above for details of
preparation) were used to induce endotoxic shock.Biophysical Journal 100(11) 2652–2661
2654 Kaconis et al.Female C57/BL6 mice (6 weeks old, 14–16 g) were purchased from
Harlan Spain (Harlan Interfauna Iberica S.A., Barcelona, Spain) and
randomly distributed in experimental groups (n ¼ 8). Endotoxic shock
was induced in the animals by co-inoculation of LPS and galactosamine
following the method of Galanos et al. (22).
Specifically, each animal received an intraperitoneal injection containing
a mixture of 25 ng of LPS of S. minnesota R60 (150 ng in the case of the
less-endotoxic LPS of P. aeruginosa PA01) and 18 mg of galactosamine
resuspended in 200 ml of endotoxin-free saline. Immediately after LPS
administration, the animals were inoculated at a different site of the perito-
neum, with the test peptide resuspended in 150 ml of pyrogen-free saline at
a LPS/peptide ratio of 1:500. To facilitate the therapeutic action of the
peptide, the mice were gently massaged at the site of inoculation for
a few seconds. Animal mortality was monitored at least every 24 h for
7 days.
In each independent experiment, a group of animals received a dose of
polymyxin B (PMB) identical to that used for the peptide, whereas another
group was left untreated.
Results regarding animal mortality at all experimental time points were
globally analyzed by means of a Kaplan-Meier survival analysis (SPSS
15.0). When the survival plots were parallel, the data were compared by
the log-rank test, whereas the Breslow-Gehan-Wilcoxon test was applied
when the plots intersected. The p-values were obtained by comparing
data from the same experiment (i.e., mortality in the treated versus the
untreated group). All of the animal protocols used in this study were
approved by the Animal Research Committee of the University of Navarra
(protocol No. 069-09).Cytotoxicity
The techniques used to detect cytotoxic effects are described in the
Supporting Material.RESULTS
In a first step, the effectivity of selected peptides (amino
acid sequence; see Table 1) to neutralize endotoxin
in vitro and in a mouse model of sepsis is described.Inhibition of the LPS-induced stimulation
of cytokines in MNCs
We investigated the ability of LPS to induce TNFa secretion
in human MNCs at 100, 10, and 1 ng/ml LPS concentra-
tions, and the results show a high cytokine production
with a slight decrease at the lowest LPS concentration
(Fig. 1 A). In all cases, the addition of the peptides
Pep19-2.5, Pep19-2.5KO, Pep19-4, and Pep19-8 leads to
a decreased secretion of TNFa, but at completely different
concentrations. Pep19-2.5 inhibits cytokine production at
an extremely low concentration, whereas at the lowest LPSTABLE 1 Sequences and molecular weights of the
investigated peptides
Pep19-2.5 GCKKYRRFRWKFKGKFWFWG 2711
Pep19-2.5KO KfGKwRfGKYRFCwKfRGwK 2711
Pep19-4 GKKYRRfRwKFKGK wfwfG 2750
Pep19-8 GRRYKKfRwKFKGRwfwfG 2636
AA identification: Bold corresponds to basic, lower case to hydrophobic,
and italic to polar character.
Biophysical Journal 100(11) 2652–2661concentration (1 ng/ml), there is almost no measurable
TNFa secretion. Of interest, for Pep19-2.5KO, which has
the same amino acids as Pep19-2.5 but in a random
sequence, there is still effective inhibition at a [Pep]/[LPS]
100:1 excess concentration ratio. The other two compounds
also differ in their ability to neutralize LPS; in particular,
compound Pep19-8 has only a weak cytokine inhibitory
ability, and a strong excess on a weight scale (100:1) is
necessary to induce some inhibition (Fig. 1 B, right-hand
bars).Animal model of endotoxicity
To ascertain whether three selected peptides (Pep19-2.5,
Pep19-4, and Pep19-8) could neutralize LPS in vivo, we
used a mouse model of acute septic shock and measured
the ability of the compounds to increase animal survival
(Fig. 2, A and B). To induce septic shock, we first used
LPS from P. aeruginosa, whose endotoxic activity is knownFIGURE 1 Inhibition of the LPS-induced inflammation reaction in vitro.
LPS R60-induced production of TNFa of human MNCs and inhibition by
Pep19-2.5 and Pep19-2.5KO (A), and Pep19-4 and Pep19-8 (B) at different
weight ratios.
FIGURE 2 Protection against lethal septic shock caused by injection of
LPS. On day 0, a group of C57/BL6 mice (n ¼%7) were inoculated intra-
peritoneally with a mixture of 18 mg of galactosamine and either (A) 150 ng
of LPS from P. aeruginosa PAO1 or (B) 25 ng of LPS from S. minnesota
R60. Immediately afterward, the animals received at a different site of
the peritoneum either 150 mg (A) or 12.5 mg (B) of the test peptide. Dupli-
cate groups of LPS-challenged animals received an amount of PMB iden-
tical to that of the peptide or were left untreated. Animal mortality was
monitored at daily intervals for 3 days. Statistical differences were analyzed
by means of the Kaplan-Meier survival test (***p < 0.001; **p < 0.01;
*p < 0.05).
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Methods). As shown in Fig. 2 A, whereas Pep19-2.5 pro-
tected the animals very efficiently, Pep19-8 showed no anti-
endotoxic activity in this model. Of interest, Pep19-4, which
displayed an intermediate level of inhibitory activity in the
cytokine assay (Fig. 1 A), showed an antiendotoxic activity
halfway between those of Pep19-2.5 and Pep19-8.
To determine whether the peptides could neutralize an
LPS of enhanced endotoxicity, we used LPS from
S. enterica serovar Minnesota R60 and tested the most
potent compound, Pep19-2.5, in the same animal model.
As shown in Fig. 2 B, administration of Pep19-2.5 conferred
a high level of protection, which was indistinguishable from
that of PMB.
Below, we characterize the physical parameters that are
prerequisites for effective LPS neutralization by the
peptides.Aggregate structure of LPS
The biologically active aggregate structure of LPSwas previ-
ously shown to have three-dimensional cubic symmetry (23).To determine the aggregate structure of LPS R60 in the pres-
ence of the peptides Pep19-2.5, Pep19-2.5KO, and Pep19-8,
we applied synchrotron radiation small-angle x-ray scat-
tering (SAXS). The scattering patterns presented in Fig. 3
for [LPS]/[peptide] 3:1 molar ratios for Pep19-2.5 show
(A) two strong reflections corresponding to the bilayer repeat
and the second order, according to previous data for LPSR60
(18). These are even more intensely expressed at 60C with
the appearance of the third and fourth order (Fig. 3, bottom).
In contrast, the data for Pep19-2.5 KO (Fig. 3 B,middle) and
Pep19-8 (Fig. 3B, bottom) are not indicative of a multilamel-
lar structure; rather, they show that a different cubic or mixed
aggregate structure is adopted. (For example, the scattering
maxima shown in Fig. 5 B, bottom, could be assigned to
8.85 nm ¼ aQ /O2, 5.52 nm¼ aQ /O5, and 4.54 nm¼ aQ /O8
of a cubic periodicity aQ ¼ 12.5 5 0.3 nm.) However, the
number of reflections is too low to obtain an unequivocal
assignment. For example, we completely exclude the possi-
bility that the reflections in the diagram in Fig. 3 B (bottom)
correspond to the two orders of two lamellar spacings. In
each case, the most important information is that the ability
of the peptide to inhibit the cytokine protection in both
invitro and invivo assays (Figs. 1 and 2) directly corresponds
to its ability to convert LPS into a multilamellar aggregate.
Thus, further measurements show that the conversion of
the basic cubic aggregate structure of LPS R60 into a multi-
lamellar form takes place for Pep19-2.5KO and Pep19-8 at
a much higher peptide concentration, i.e., at a molar excess
of the peptide (data not shown).
The morphologies of the pure LPS samples and the
mixtures with peptide Pep19-2.5 investigated with freeze-
fracture electron microscopy are shown in Fig. 4. LPS alone
exhibits ribbon-like structures with lengths up to a few
hundred mm (see inset), thicknesses of 14–20 nm, and vari-
able widths (A). In the presence of LPS (B), these separated
structures change completely into large and densely packed
multilamellar aggregates, with many multilamellar stack-
ings corresponding to the multiple lamellae found in the
x-ray experiment.Neutralization of the LPS headgroup charges
We next sought to investigate the ability of a given peptide to
neutralize the negative surface charges of an LPS sample. To
that end, we applied isothermal titration calorimetry (ITC)
and electrophoretic mobility determination to determine
the z-potential. ITC has been shown to be a sensitive and
direct means of determining the strength of a binding
complex (13). The ITC data for the three selected peptides
are given in Fig. 5 A. All single titrations (for example, repre-
sentation of the power versus time in the diagram at the top of
the figure) indicate negative values corresponding to a strong
exotherm of the binding of the peptides to LPS, which disap-
pear at different concentrations for the three peptides. The
presentation of the integrals of these exotherms (diagramsBiophysical Journal 100(11) 2652–2661
FIGURE 3 Supramolecular aggregate structure of LPS. SAXS was per-
formed using synchrotron radiation of LPS R60 in the presence of
Pep19-2.5 at (A) three temperatures and (B) at 40C in the presence of
Pep19-2.5 (top), Pep19-2.5KO (middle), or Pep19-8 (bottom). All samples
were prepared at [LPS]/[Pep] 3:1 weight %. The logarithm of the scattering
intensity logI is plotted versus the scattering vector s (¼ 1/d, d ¼ lattice
spacings).
Biophysical Journal 100(11) 2652–2661
2656 Kaconis et al.at the bottom of the figure) shows a transition into binding
saturation at different peptide/LPS ratios. Whereas the
Pep19-2.5/LPS system is already in saturation at molar
ratios< 0.4, for the other peptides this value isR1.1. There-
fore, the binding affinity of Pep19-2.5 is much higher than
those for the other peptides. A more precise ITC experiment
was performed with the latter peptide (Fig. 5 B). The evalu-
ation of such curves from five independent experiments,FIGURE 4 Morphology of LPS aggregates. Freeze-fracture micrographs
of LPS R60 and LPS/peptide mixtures. (A) LPS alone shows aggregates of
ribbon-like structures appearing more or less cross fractured (area marked
by star) or tangentially fractured (area marked by triangle). The extension
of the ribbons is more clearly visible in the case of adsorbed ribbons (inset).
(B) After addition of Pep19-2.5, multilamellar aggregates are visible.
FIGURE 5 (A) Binding saturation of peptides. ITC of mixtures of LPS
R60 with Pep19-2.5 (top), Pep19-2.5KO (middle), and Pep19-8 (bottom)
at 37C. For the LPS dispersion (0.05 mM), 5 ml of the peptide solution
(2 mM) was titrated every 5 min, and the calorimetric signal was recorded.
(B) Binding saturation of peptides. ITC of mixtures of LPS R60 with
Pep19-2.5 (LPS concentration: 0.05 mM; Pep19-2.5 concentration:
2 mM). The measurements were done at 37C.
FIGURE 6 Compensation of LPS backbone charges. The z-potential of
LPS R60 aggregates depends on different concentrations of Pep19-8 and
Pep19-2.5, as determined by their electrophoretic mobility with Laser-
Doppler anemometry.
Endotoxin Neutralization 2657using a sigmoidal saturation curve as shown in Fig. 5 B, gave
a binding constant of k ¼ (2.85 3.0)  108 /Mol.
We determined the z-potential of the LPS/peptide
mixtures by measuring their electrophoretic mobilities. A
comparison of Pep19-2.5 with Pep19-8 (Fig. 6) shows that
the z-potential, starting from negative values due to the
negative lipid A backbone charges, does not end at zero
potential. Instead, it adopts clearly positive values, i.e., addi-tional binding occurs beyond pure charge compensation. Of
interest, the less-active Pep19-8 reaches a positive z-poten-
tial at significantly lower LPS/peptide ratios than the highly
active Pep19-2.5. Thus, in addition to purely electrostatic
interactions, hydrophobic interactions between the lipid
and the peptides have to be considered.Peptide incorporation into phospholipid and LPS
membranes
We investigated the ability of the peptides Pep19-2.5,
Pep19-2.5KO, and Pep19-8 to intercalate into phospholipid
membranes from PC, phosphatidylserine (PS), and LPS by
applying FRET (Fig. S3, A–C).LPS inactivation in the Limulus test
In the Limulus amoebocyte lysate test, which is a very sensi-
tive test for endotoxin contamination, the recognition struc-
ture for LPS is the diglucosamine 40-phosphate backbone
region (24). The data in Fig. 7 show a complete inhibition
of endotoxic activity (in endotoxin units (EUs)) at all
concentrations of LPS (10, 1, and 0.1 ng/ml) and an [LPS]/
[Pep19-2.5] weight ratio of 1:1. Thus, binding of the peptide
to the 40-phosphate should take place very effectively.Influence of peptides on a membrane mimetic
bilayer
We investigated the influence of the peptide 19-2.5 on the
mimetic of the immune cell membrane as described above
by applying SAXS (Fig. 8). As can be seen in the figure,
this mixed lipid system exhibits a bilayer periodicity of
5.05 nm with a shoulder at 4.65 nm and an additional reflec-
tion at 7.46 nm (top). The latter reflection may reflect three-
dimensional phase separation of SM (see Discussion). The
first two values may correspond to different periodicitiesBiophysical Journal 100(11) 2652–2661
FIGURE 7 Biological activity in the Limulus test system. The activities
(in EUs) of LPS R60 and LPS/Pep19-2.5 mixtures in the Limulus amebo-
cyte lysate test at three different LPS concentrations and LPS/Pep ratios
of 1:1–1:30 weight % are shown. As the standard in this test, the LPS
S-form from E. coli O111 is used; 1 ng of LPS corresponds to 14.6 EUs.
FIGURE 8 Aggregate structure of a mimetic of the mammalian phospho-
lipids membrane. SAXS was performed using synchrotron radiation of
DOPC/SM/Cho mixtures 9:9:2 molar in the presence of Pep19-2.5 at three
2658 Kaconis et al.due to the domain structures of this lipid mixture. Upon
addition of Pep19-2.5 (middle, bottom), the main periodicity
hardly changes, whereas the values corresponding to the
domains change, i.e., the domain structure changes.molar ratios 1:0 (top), 2:1 (middle), and 1:2 (bottom) at 40C. The loga-
rithm of the scattering intensity logI is plotted versus the scattering vector
s (¼ 1/d, d ¼ lattice spacings).Cytotoxicity of the peptides
The cytotoxic effects of the peptides are described in the
Supporting Material.DISCUSSION
Our aim in this systematic study of the mechanisms of inter-
action of selected SALPs with LPS (endotoxin) and with
eukaryotic membrane systems was to characterize both the
neutralization mechanisms of LPS and the selectivity of
these processes in different membrane systems. The data
clearly show that the selected SALPs differ strongly in their
ability to suppress the cytokine response in human MNCs
(Fig. 1), and to confer protection in the animal model of
sepsis (Fig. 2). We analyzed various physical parameters
to find out whether they are determinants of the inactivation
process of LPS.
A comparison of the data for the gel-to-liquid crystalline
phase behavior reveals that the Pep19-2.5 peptide with the
highest inhibitory activity results in only a slight fluidization
of the acyl chains (Fig. S1 A), whereas the Pep19-8 peptide
with much lower inhibitory activity shows a stronger fluid-
ization (Fig. S1 B). It was previously shown that the gold
standard of AMPs, PMB, leads to a strong acyl chain fluid-
ization of LPS (25). However, its nonapeptide, PMBN,
behaved nearly identically to PMB, although this compoundBiophysical Journal 100(11) 2652–2661exhibits no or only low antimicrobial activity (26). There-
fore, the parameter fluidization of the acyl chains of the lipid
A moiety of LPS by itself does not correlate with the
capacity of a peptide to block the stimulation capacity of
LPS. This is also in accord with a previous study of the in-
hibiting effect of human lactoferrin on LPS-induced cell
stimulation, which showed that the binding of LF to LPS
leads to acyl-chain rigidification (4).
Various studies have emphasized the importance of the
aggregate structure of endotoxins for the expression of bio-
logical activity. In one study, cubic aggregate structures
were assigned to their bioactive structure, whereas the inhi-
bition induced by AMPs converted these into a multilamellar
assembly (23). The diffraction patterns seen here do not give
strong evidence for cubic phases, which may reflect the fact
that it was our aim to realize near-physiological conditions,
i.e., a water content >95%, whereas cubic phases for LPS
are well expressed at 70–85% water content (18). However,
the most important finding is that the extent of multilamel-
larization directly correlates with the biological efficiency
of the single peptides (Figs. 1, 2, and 3 B), as evidenced
by the fact that compound Pep19-8, which has the lowest
inhibition capacity, maintained the original aggregate struc-
ture more strongly than the more-active compounds.
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increase in the size of the aggregate structures (Fig. 4),
with small ribbon-like structures changing into large,
agglomerated, three-dimensional patches in which expanded
multilamellar stackings are found in correspondence to the
SAXS data.
The literature contains only limited data regarding
changes in LPS aggregate structures and sizes due to the
action of peptides. Rosenfeld et al. (27,28) studied the inhib-
iting effects of different peptides on the stimulating capacity
of S-form LPS and concluded that peptide binding to LPS is
accompanied by a dissociation of the LPS aggregates. They
based their conclusions on the results of FITC-labeled LPS
and fluorescence dequenching experiments, in which an
increase of the fluorescence intensity was interpreted as re-
sulting from a disaggregation process. It is known, however,
that other effects, such as an increase of the LPS acyl-chain
fluidity, may also be connected to an increase in fluorescence
intensity (K. Brandenburg, unpublished results), and that in
both cases, the binding of LPS to LBP, as well as to BPI,
lead to a fluorescence increase due to dequenching, although
the former protein should result in a disaggregation, and the
latter in an complexation, i.e., an increase in aggregation
(29). Furthermore, using negative-staining electron micros-
copy, Rosenfeld et al. found a decrease in aggregate size.
This can be understood in the light of the fact that the aggre-
gational behavior of LPS is extremely dependent on the
water content, leading to completely different phases when
water is removed from the dispersions, i.e., the inherent
cubic aggregates of enterobacterial lipid A and LPS would
convert into multilamellar complexes at ~%50% water
content (30,31). Another possibility would be a different
mechanism as described by Rosenfeld et al., because these
authors used S-form LPS, which has a rather high heteroge-
neity. The aggregate structure of this complex mixture is not
known in detail; therefore, other mechanisms may be
involved. To resolve these differences, we plan to conduct
experiments with LPS S-form from Escherichia coli, which
is similar to the S-form LPS used by Rosenfeld et al. Wewill
perform electron microscopic analyses using special cryo-
techniques, including cryo-transmission electron micros-
copy and freeze-fracturing (32).
The ITC data are important for an interpretation of the
peptide-induced inhibition of the cell stimulation by LPS.
The strong exothermic reaction of the LPS peptide interac-
tion, found for all peptides due to Coulomb interaction
between the positive charges of the peptides and the nega-
tive backbone charges of LPS, is already in saturation at
[Pep19-2.5]/[LPS] ¼ 0.3, i.e., three peptide molecules per
10 LPS molecules already lead to charge saturation. In
contrast, for the much less effective compounds Pep19-
2.5KO and Pep19-8, saturation is reached at [Pep]/[LPS]
molar ratios of >1 (Fig. 5). The strong inhibitory capacity
of Pep19-2.5 can be explained by the high binding constant
(estimated as k ¼ 2.8  108 /Mol from Fig. 5) of thepeptide to LPS putatively exceeding that for the human
LPS-binding proteins LBP and CD14, which are responsible
for the initial steps of cell activation. It should be mentioned
that such binding constants of LPS with LBP and CD14
have been reported to lie in the range of 108 to 109/Mol
(33,34). These data were obtained by using FITC-labeled
or 3H-metabolically labeled LPS from S. minnesota R595.
Since binding constants measured with other techniques,
which afford the use of labels, frequently differ strongly
from values reported with ITC, comparative measurements
should be done. We will address this question in a separate
investigation.
An important inactivation step is the competitive interac-
tion of the peptide with human binding proteins such as LBP
and CD14. However, this may not be the only step that is
important for understanding LPS neutralization. The
FRET data indicate an intercalation of the peptides not
only into LPS aggregates (Fig. S3 C), which is in accord
with the above-discussed data, but also into normal PC (or
DOPC/SM/Chol mixtures) and PS liposomal membranes
(Fig. S3, A and B). Together with the observation that the
neutralization ability of Pep19-2.5 is still present when it
is administered up to 3 h after LPS addition (data not
shown), and the reported data that LPS by itself is trans-
ported into target membranes by the action of LBP (35),
a second step in LPS neutralization is the interaction of
LPS and peptides within the membranes of immune cells.
The details and mechanisms of this interaction will be pre-
sented in a separate study.
It was previously shown that the potential binding sites in
LPS, the phosphates, differ by their conformation, with the
1-phosphate looking into the aqueous environment of the
LPS layer, and the 40-phosphate sticking into the hydro-
phobic/interface region (36). In similarity to what was
recently reported for cyclic peptides based on the Limulus-
anti LPS factor (20), we found that the 1-phosphate is the
first point of binding of the peptide (IR fingerprint region;
Supporting Material). This is in excellent agreement with
the data from the Limulus assay (Fig. 7), which unequivo-
cally indicate a complete blocking of the reaction at LPS/
Pep19-2.5 1:1 weight %. It was previously reported that
the presence of an acylated diglucosamine 40-phosphate
headgroup of LPS/lipid A is a prerequisite for Limulus
activity (24).
For therapeutic use, the question of the specificity of the
SALP, or, in pharmacological terms, the therapeutic index,
is of utmost importance. This corresponds to the ratio of
the dose at which side effects occur to the therapeutic
dose. Here, the in vitro data of the cytotoxicity and hemo-
lysis (Fig. S4, A and B) are indicative of the beginning of
adverse effects at concentrations of 30–50 mg/ml, whereas
the therapeutic dose (Fig. 2) is ~1 mg/ml. In support of these
findings are the SAXS experiments of the interaction of
Pep19-2.5 with a mimetic of an immune cell membrane
(DOPC/SM/Chol 9:9:2 molar ratio). Various authors haveBiophysical Journal 100(11) 2652–2661
2660 Kaconis et al.investigated such membrane models with variations in the
single components (37–39). In the light of their data, it
can be concluded that the SM exhibits a three-dimensional
phase separation, which can be deduced from the extra
reflection at 7.46 nm in Fig. 8 (top). This reflection disap-
pears in the presence of the peptide, which apparently is
a result of the membrane incorporation as described above.
Of most importance, however, is the observation that the
basic structure and hence its integrity are maintained, in
accordance with the determination of cytotoxic effects.
A previous study in mice showed that a considerable
degree of protection occurs at [Pep19-2.5]/[LPS] 50:1
weight % (10), shifting the therapeutic index to even higher
values. Although these are preclinical data, obtained in
galactosamine-sensitized mice, the application of this
peptide to humans should render similar results. Humans
can experience severe septic syndromes at LPS concentra-
tions of <0.5 ng/ml in blood (40). The therapeutic dose of
the peptide should be in the range of 100:1–1000:1 with
respect to LPS, i.e., it should not exceed 1 mg/ml, in simi-
larity to the situation in the animal model.SUPPORTING MATERIAL
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